Link to this page
STO
Last uploaded:
November 28, 2017
Jump to:
| Id | http://www.semanticweb.org/ontologies/STO.owl#OWLClass_8bc22209_b564_4f6f_b14b_4fbbb2731f82
http://www.semanticweb.org/ontologies/STO.owl#OWLClass_8bc22209_b564_4f6f_b14b_4fbbb2731f82
|
|---|---|
| Preferred Name | abciximab |
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| label |
abciximab
|
|---|---|
| prefLabel |
abciximab
|
| hasDbXref | |
| references |
Abciximab in Ischemic Stroke Investigators. (2000). Abciximab in Acute Ischemic Stroke A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study. Stroke, 31(3), 601-609.
|
| isDefinedBy |
Abciximab (ReoPro) is the Fab fragment of a chimeric human/mouse monoclonal antibody directed against the platelet glycoprotein IIb/IIIa (GP IIb/IIIa) receptor, the final mediator of aggregation. Abciximab appears to be safe when administered up to 24 hours after stroke onset, and it might improve functional outcome.
|
| prefixIRI |
OWLClass_8bc22209_b564_4f6f_b14b_4fbbb2731f82
|
| subClassOf | |
| type |
Add comment
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |